While erythropoietin can disengage macrophagesby stopping the activity of NF-κB, itis possible that one of the mechanisms explainingthe antifibrotic effects of erythropoietin inchronic kidney disease is in vivo macrophageregulation (20-25). This evidence concerns the gene EPO and kidney disorder.